EIDD-2801 (beta-D-N4hydroxycytidine-5’-isopropyl ester).
Orally available prodrug of nucleoside analog inhibitor.
Activity in mouse SARS-CoV and MERS-CoV infection models.
Effective against remdesivir-resistant strains.
Highly important preprint.
biorxiv.org/content/10.110…
Orally available prodrug of nucleoside analog inhibitor.
Activity in mouse SARS-CoV and MERS-CoV infection models.
Effective against remdesivir-resistant strains.
Highly important preprint.
biorxiv.org/content/10.110…
Most promising--by far--prospect on vaccine and antiviral front (which otherwise has offered only hype and retreads).
High priority to see EIDD-2801, or a combination of EDDD-2801 and remdesivir, in higher mammals.
High priority to see EIDD-2801, or a combination of EDDD-2801 and remdesivir, in higher mammals.
Compound originally was developed by Plemper and co-workers at Emory as an anti-influenza agent.
stm.sciencemag.org/content/11/515…
stm.sciencemag.org/content/11/515…
Prodrug of beta-D-N4-Hydroxycytidine, which was developed by Flolovm Frolova, and co-workers at Emory as an in vitro anti-VEEV agent.
ncbi.nlm.nih.gov/pmc/articles/P…
ncbi.nlm.nih.gov/pmc/articles/P…
Important to note that entire development sequence--from in vitro antiviral agent, to orally available in vivo antiviral agent, to orally available in vivo anti-coronavirus agent--was funded by grants from National Institutes of Health (@NIAIDFunding; @NIAIDFunding).
* Frolov,
